C. Jacobs John's Insider Trades & SAST Disclosures
C. Jacobs John's most recent trade in Novavax, Inc. was a trade of 676,000 2025 Non-statutory Stock Option NQ done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern C. Jacobs John.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 676,000 | 676,000 | - | - | 2025 Non-statutory Stock Option NQ | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 450,500 | 450,500 | - | - | 2025 Restricted Stock Units RSU | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 83,334 | 166,666 | - | - | Restricted Stock Units | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 83,334 | 175,183 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.33 per share. | 01 Mar 2025 | 38,451 | 136,732 (0%) | 0% | 8.3 | 320,297 | Common Stock |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 83,196 | 130,722 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 83,196 | 83,197 | - | - | Restricted Stock Units | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.55 per share. | 23 Jan 2025 | 38,873 | 91,849 (0%) | 0% | 9.5 | 371,237 | Common Stock |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 250,000 | 250,000 | - | - | Restricted Stock Units | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 83,197 | 83,197 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | C. Jacobs John | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 83,197 | 166,393 | - | - | Restricted Stock Units | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.26 per share. | 23 Jan 2024 | 40,093 | 43,104 (0%) | 0% | 4.3 | 170,796 | Common Stock |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 290,700 | 290,700 | - | - | Stock Option (Right to buy) | |
| Novavax, Inc. | John C. Jacobs | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 249,590 | 249,590 | - | - | Restricted Stock Units | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, PRESIDENT, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 40,000 | 114,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, PRESIDENT, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 15 Aug 2022 | 40,000 | 40,000 | - | 8.2 | 328,800 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, PRESIDENT, CEO | Sale of securities on an exchange or to another person at price $ 51.05 per share. | 15 Aug 2022 | 39,091 | 909 | - | 51.1 | 1,995,760 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, PRESIDENT, CEO | Sale of securities on an exchange or to another person at price $ 51.76 per share. | 15 Aug 2022 | 909 | 0 | - | 51.8 | 47,053 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 154,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | 8.2 | 123,300 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.38 per share. | 15 Jun 2022 | 14,200 | 800 | - | 45.4 | 644,370 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 46.13 per share. | 15 Jun 2022 | 800 | 0 | - | 46.1 | 36,907 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2022 | 25,000 | 169,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 13 Jun 2022 | 25,000 | 25,000 | - | 8.2 | 205,500 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 44.53 per share. | 13 Jun 2022 | 15,197 | 0 | - | 44.5 | 676,675 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 43.63 per share. | 13 Jun 2022 | 9,803 | 15,197 | - | 43.6 | 427,735 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.32 per share. | 16 Mar 2022 | 15,000 | 0 | - | 45.3 | 679,821 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 16 Mar 2022 | 15,000 | 15,000 | - | 8.2 | 123,300 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 15,000 | 194,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 14 Mar 2022 | 25,000 | 25,000 | - | 8.2 | 205,500 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2022 | 25,000 | 209,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.06 per share. | 14 Mar 2022 | 12,456 | 12,544 | - | 42.1 | 523,871 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.66 per share. | 14 Mar 2022 | 11,614 | 930 | - | 42.7 | 495,474 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 43.47 per share. | 14 Mar 2022 | 930 | 0 | - | 43.5 | 40,427 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 03 Jan 2022 | 18,053 | 18,053 | - | 8.2 | 148,396 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 18,053 | 234,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.15 per share. | 03 Jan 2022 | 18,053 | 0 | - | 45.1 | 815,050 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 10,647 | 252,804 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 03 Jan 2022 | 10,647 | 10,647 | - | 8.2 | 87,518 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.17 per share. | 03 Jan 2022 | 10,647 | 0 | - | 45.2 | 480,936 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.03 per share. | 27 Dec 2021 | 1,300 | 0 | - | 45.0 | 58,538 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 1,300 | 263,451 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 27 Dec 2021 | 1,300 | 1,300 | - | 8.2 | 10,686 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 13 Dec 2021 | 25,000 | 25,000 | - | 8.2 | 205,500 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 25,000 | 264,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 38.02 per share. | 13 Dec 2021 | 13,140 | 11,860 | - | 38.0 | 499,629 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 38.43 per share. | 13 Dec 2021 | 11,860 | 0 | - | 38.4 | 455,780 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.93 per share. | 13 Sep 2021 | 25,000 | 0 | - | 35.9 | 898,263 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 25,000 | 289,751 | - | - | Stock Option | |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.22 per share. | 13 Sep 2021 | 25,000 | 25,000 | - | 8.2 | 205,500 | Common Stock |
| Harmony Biosciences Holdin... | John C. Jacobs | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2020 | 144,856 | 144,856 | - | - | Stock Option |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges